Jeffrey H. Murray

Array ( [id] => 16925235 [patent_doc_number] => 11046696 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-29 [patent_title] => Fused pyrimidine compound or salt thereof [patent_app_type] => utility [patent_app_number] => 15/930554 [patent_app_country] => US [patent_app_date] => 2020-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 4 [patent_no_of_words] => 66607 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 366 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15930554 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16925235 [patent_doc_number] => 11046696 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-29 [patent_title] => Fused pyrimidine compound or salt thereof [patent_app_type] => utility [patent_app_number] => 15/930554 [patent_app_country] => US [patent_app_date] => 2020-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 4 [patent_no_of_words] => 66607 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 366 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15930554 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16283698 [patent_doc_number] => 20200277300 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => CDK INHIBITORS [patent_app_type] => utility [patent_app_number] => 15/931330 [patent_app_country] => US [patent_app_date] => 2020-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16182 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15931330 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16861675 [patent_doc_number] => 11020397 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-01 [patent_title] => Compounds and their use for reducing uric acid levels [patent_app_type] => utility [patent_app_number] => 16/872629 [patent_app_country] => US [patent_app_date] => 2020-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 56 [patent_no_of_words] => 42593 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 214 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16872629 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16437019 [patent_doc_number] => 20200354345 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-12 [patent_title] => MODULATORS OF THR-BETA AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/869211 [patent_app_country] => US [patent_app_date] => 2020-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 87571 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16869211 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16421910 [patent_doc_number] => 20200347108 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-05 [patent_title] => Peptide Conjugates Incorporating Urea Elements and Their Use as Vaccines [patent_app_type] => utility [patent_app_number] => 16/864348 [patent_app_country] => US [patent_app_date] => 2020-05-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8792 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16864348 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16613561 [patent_doc_number] => 20210032214 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-04 [patent_title] => COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 [patent_app_type] => utility [patent_app_number] => 16/861166 [patent_app_country] => US [patent_app_date] => 2020-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37871 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16861166 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17889777 [patent_doc_number] => 11452724 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-27 [patent_title] => Methods for treating amyotrophic lateral sclerosis [patent_app_type] => utility [patent_app_number] => 16/855623 [patent_app_country] => US [patent_app_date] => 2020-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 10 [patent_no_of_words] => 5988 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16855623 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16312254 [patent_doc_number] => 20200290992 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-17 [patent_title] => Deuterium-Substituted Pyridin- And Pyrimidin-2-yl-Methylamine Compounds [patent_app_type] => utility [patent_app_number] => 16/853250 [patent_app_country] => US [patent_app_date] => 2020-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24882 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16853250 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16204683 [patent_doc_number] => 20200237673 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-30 [patent_title] => PHARMACEUTICAL FORMULATIONS OF A BRUTON'S TYROSINE KINASE INHIBITOR [patent_app_type] => utility [patent_app_number] => 16/846064 [patent_app_country] => US [patent_app_date] => 2020-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48262 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16846064 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17119636 [patent_doc_number] => 11130758 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-09-28 [patent_title] => Tetrahydropyrazolopyrimidine compounds [patent_app_type] => utility [patent_app_number] => 16/845594 [patent_app_country] => US [patent_app_date] => 2020-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 80 [patent_figures_cnt] => 93 [patent_no_of_words] => 30705 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 1284 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16845594 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19311538 [patent_doc_number] => 12037341 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-16 [patent_title] => Process for preparing bicyclic enolether [patent_app_type] => utility [patent_app_number] => 17/299405 [patent_app_country] => US [patent_app_date] => 2020-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3694 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 113 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17299405 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17652256 [patent_doc_number] => 11354990 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-06-07 [patent_title] => Treatment of kidney diseases associated with elevated AVP [patent_app_type] => utility [patent_app_number] => 16/841098 [patent_app_country] => US [patent_app_date] => 2020-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 12 [patent_no_of_words] => 15730 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16841098 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16955961 [patent_doc_number] => 11059801 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-07-13 [patent_title] => Methods to induce targeted protein degradation through bifunctional molecules [patent_app_type] => utility [patent_app_number] => 16/838656 [patent_app_country] => US [patent_app_date] => 2020-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 48 [patent_figures_cnt] => 115 [patent_no_of_words] => 73177 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 360 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16838656 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16261215 [patent_doc_number] => 10752634 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-08-25 [patent_title] => Crystalline forms of a brutons tyrosine kinase inhibitor [patent_app_type] => utility [patent_app_number] => 16/837665 [patent_app_country] => US [patent_app_date] => 2020-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 37277 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16837665 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16360927 [patent_doc_number] => 20200317678 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-08 [patent_title] => HEPATITIS B ANTIVIRAL AGENTS [patent_app_type] => utility [patent_app_number] => 16/834259 [patent_app_country] => US [patent_app_date] => 2020-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18419 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16834259 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16908949 [patent_doc_number] => 11040974 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-22 [patent_title] => Crystalline linagliptin intermediate and process for preparation of linagliptin [patent_app_type] => utility [patent_app_number] => 16/832067 [patent_app_country] => US [patent_app_date] => 2020-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 2878 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16832067 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17748096 [patent_doc_number] => 20220226299 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-21 [patent_title] => USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS [patent_app_type] => utility [patent_app_number] => 17/599271 [patent_app_country] => US [patent_app_date] => 2020-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51241 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -75 [patent_words_short_claim] => 129 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17599271 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17526816 [patent_doc_number] => 11299487 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-04-12 [patent_title] => Compounds and compositions as modulators of TLR signaling [patent_app_type] => utility [patent_app_number] => 16/830110 [patent_app_country] => US [patent_app_date] => 2020-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 67464 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 440 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16830110 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16345100 [patent_doc_number] => 20200309750 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-01 [patent_title] => REAGENT COMPOSITIONS AND METHOD FOR KARL FISCHER TITRATION [patent_app_type] => utility [patent_app_number] => 16/827163 [patent_app_country] => US [patent_app_date] => 2020-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6946 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 146 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16827163 [rel_patent_id] =>[rel_patent_doc_number] =>)